Ventripoint Diagnostics and Montecristo Group Partner to Expand Cardiac Screening in Costa Rica

Toronto, Ontario — April 2, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) is partnering with the Health Division of the Montecristo Group to explore the implementation of Ventripoint’s VMS+™ cardiac imaging platform in Costa Rica.

The collaboration will focus on expanding access to advanced cardiac diagnostics, including remote screening for congenital and structural heart disease. It also aims to integrate VMS+™ technology into clinical research and clinical trial programs, as well as broaden the deployment of VMS+™ AI-assisted echocardiography solutions for patients throughout Costa Rica. The goal is to improve the accuracy of heart monitoring and increase access to modern diagnostic tools for both public and private healthcare systems.

The organizations will explore how the VMS+™ system can support hospitals, physicians, and research organizations by enhancing the accuracy of cardiac imaging and enabling earlier detection of heart conditions, particularly in underserved or remote communities.

Hugh MacNaught, President & CEO of Ventripoint Diagnostics, said the company is excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica. He cited their strong healthcare network, commitment to affordable high-quality care, and passion for innovation as reasons that make them an ideal partner as Ventripoint works to expand access to advanced cardiac diagnostics and support clinical research opportunities in central America.

Catalina Ulloa, Director of the Metropolitano Research Institute, Hospital Metropolitano, Grupo Montecristo, said they are proud to serve as the research partner of Ventripoint Diagnostics in Costa Rica. Ulloa said that leveraging their expertise in clinical research execution and large-scale screening deployment in Costa Rica, this partnership enables them to translate advanced AI-driven cardiac imaging into real-world impact by expanding early detection, improving diagnostic accuracy, and increasing access to high-quality cardiovascular care.

The collaboration is expected to support research partnerships, technology deployment initiatives, and clinical trial (CRO) programs that incorporate VMS+ as an affordable advanced cardiac measurement tool that supports new care models and pathways.

The Health Division of the Montecristo Group is part of one of Costa Rica’s leading corporate groups, focused on advancing healthcare access, innovation, and patient-centered medical services. The division works to provide high-quality medical care, promote preventative health, and introduce innovative healthcare solutions that improve wellbeing for communities across Costa Rica and the region through a network of healthcare companies and medical facilities, including Hospital Metropolitano and other specialized health services.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which provides accurate volumetric cardiac measurements equivalent to MRI. Ventripoint's affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Source: Ventripoint Diagnostics Ltd.